Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Enters Strategic Collaboration to Explore Innovative Products and Medical Solutions

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced its entry into a cooperation agreement with Roche Pharmaceuticals China (“Roche”) to leverage both parties’ advantages and sources to explore novel health care and medical solutions and collaboration models in early cancer screening, early diagnosis and early treatment. According to the update, AnPac Bio and Roche will jointly explore personalized product lines and solutions and will target the general population for early cancer screening, hospital diagnosis, and precision medicine through therapy selection testing. The synergistic collaboration plans to form a competitive package of products and services to enhance cancer screening and follow-up tests, improve customers’ affordability, and help customers to receive more innovative, affordable and high-quality health care and medical services.

To view the full press release, visit https://ibn.fm/WpCrf

About AnPac Bio-Medical Science Co. Ltd.

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021. With two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. According to Frost & Sullivan, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 41,700 clinical samples as of December 31, 2019. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity. For more information, visit www.AnpacBio.com.

NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

This entry was posted in AnPac Bio-Medical Science Co. Ltd. ANPC, MissionIRNewsBreaks. Bookmark the permalink.

Comments are closed.